Latest Drug News | Top Drug News Headlines Today | Today India news | Breaking Drug News Today | English Drug News Headlines - TheDailyGuardian

Kolkata Man Arrested for Smuggling LSD Tattoo Stickers via Dark Web

February 22, 2025, 7:01 pm

A 27-year-old Mohammad Shahbaz from Kolkata was arrested for allegedly peddling LSD laced children’s tattoo stickers from the dark web using cryptocurrency. He was nabbed on Wednesday in Sector 43, Gurugram. The police officers recovered 2.7 grams of LSD stamped on stickers resembling children’s tattoos, intended for sale at elite parties.

Unmasked Drug Trade by Shahbaz

Shahbaz, who was living in New Town, Kolkata, was residing in a rented place in Saket, Delhi. He was apprehended with the LSD-laced stickers following a tip-off by men of the Anti-Narcotics Cell under the supervision of a gazetted officer. According to authorities, the stickers resembled ordinary tattoos for children, making them difficult to detect even with drug scanners.

“These drug-laced stickers are nearly indistinguishable from regular children’s tattoos, making their identification extremely challenging,” explained Sub-Inspector Karamjit, the officer who led the operation.

LSD Born from Cryptocurrency

After interrogation, Shahbaz agreed to have procured the high-intensity hallucinogenic drug from an international dark web portal called Bioness. For payment, he used only cryptocurrency in order to prevent detection. It is suspected that he wanted to distribute the drugs in Gurugram amongst affluent partygoers.

Against him, an FIR was filed under Section 22(c) of the Narcotic Drugs and Psychotropic Substances (NDPS) Act. Authorities are also launching a probe to trace his potential connections abroad and find out about other persons of that network. All this happened at the Sushant Lok police station.LSD on the Rise in India

A senior investigating officer revealed, “LSD is gaining immense popularity among the youth of India, particularly in underground rave parties. The substance has become an instant hit in the US, Russia, and Europe but, riding that wave, even India now seems to be catching the trend.”

FDA Approves First-Ever Drug to Combat Sleep Apnea

December 24, 2024, 2:47 pm

US FDA Approves First-Ever Drug To Combat Sleep Apnea

Sleep apnea, a serious and often underdiagnosed sleep disorder, affects millions of people worldwide. It is characterized by frequent interruptions in breathing during sleep, which can lead to fragmented sleep, increased risk of cardiovascular issues, and other health complications. While treatments for sleep apnea have existed for years, primarily focusing on mechanical devices like Continuous Positive Airway Pressure (CPAP) machines, the approval of the first-ever drug to combat sleep apnea marks a significant advancement in managing this condition. This breakthrough offers hope to the millions of individuals who struggle with sleep apnea and seek alternative treatment options. In this article, we will explore the significance of this FDA approval, the science behind the new drug, and its potential impact on sleep apnea treatment.

Understanding Sleep Apnea

Before diving into the approval of the new drug, it’s important to understand what sleep apnea is, how it affects the body, and the current treatments available.

What is Sleep Apnea?

Sleep apnea is a disorder in which a person’s breathing repeatedly stops and starts during sleep. The most common type is obstructive sleep apnea (OSA), which occurs when the muscles at the back of the throat relax excessively during sleep, leading to a temporary obstruction of the upper airway. Another type, central sleep apnea, occurs when the brain fails to send the correct signals to the muscles that control breathing. Complex sleep apnea syndrome is a combination of both obstructive and central sleep apnea.

Symptoms and Risks

The hallmark symptoms of sleep apnea include loud snoring, choking or gasping for air during sleep, and extreme daytime fatigue. These symptoms often lead to poor sleep quality, which can cause irritability, memory problems, and a decreased ability to concentrate. However, the risks associated with sleep apnea extend far beyond just disrupted sleep.

Untreated sleep apnea can lead to serious health conditions, such as:

Cardiovascular problems: Sleep apnea is linked to high blood pressure, heart attacks, stroke, and atrial fibrillation.
Diabetes: The disorder is associated with insulin resistance and type 2 diabetes.
Daytime fatigue and accidents: The persistent fatigue caused by interrupted sleep can increase the risk of accidents, including motor vehicle crashes.
Cognitive decline: Long-term sleep apnea can lead to memory issues, poor concentration, and a higher risk of neurodegenerative diseases such as dementia.
Mental health issues: Anxiety and depression are common among people with untreated sleep apnea.

With such significant health implications, effective treatment for sleep apnea is crucial.

The Current Landscape of Sleep Apnea Treatment

Historically, the treatment of sleep apnea has focused primarily on mechanical interventions. The CPAP machine is the most widely known device used to treat obstructive sleep apnea. It works by providing a constant stream of air through a mask to keep the airway open during sleep. While effective, CPAP therapy can be cumbersome and uncomfortable for many individuals, leading to poor adherence to treatment.

For individuals who cannot tolerate CPAP, other treatment options include:

Positive airway pressure devices: Variations of CPAP, such as bilevel positive airway pressure (BiPAP), offer different settings to make breathing easier.
Oral appliances: Dental devices that reposition the lower jaw or tongue to keep the airway open can be used for mild to moderate sleep apnea.
Surgery: In some cases, surgical intervention may be necessary to remove excess tissue from the throat or reposition the jaw to improve airflow.
Lifestyle changes: Weight loss, sleep position changes, and avoiding alcohol or sedatives can help alleviate mild cases of sleep apnea.

Despite the variety of treatment options, these interventions are not suitable for all patients. This has led to a growing demand for pharmaceutical treatments that could complement or replace existing therapies, providing an alternative for those who cannot tolerate mechanical devices.

The Breakthrough: FDA Approval of the First-Ever Drug for Sleep Apnea

In a groundbreaking move, the U.S. Food and Drug Administration (FDA) has approved the first-ever drug specifically designed to combat sleep apnea. This approval is a significant milestone in the management of this disorder, offering patients a non-invasive, alternative option to mechanical therapies like CPAP.

The New Drug: Mechanism of Action

The newly approved drug works by targeting the muscles of the upper airway, specifically the muscles that tend to relax and collapse during sleep in patients with obstructive sleep apnea. By stimulating these muscles, the drug helps to prevent the airway from becoming blocked, ensuring that the patient’s breathing remains unobstructed throughout the night. The medication is taken before bedtime, and its effects are designed to last throughout the sleep cycle, thus preventing apneas and hypopneas (partial obstructions).

The drug’s active ingredient is a prodrug, meaning that it is inactive until metabolized in the body, at which point it becomes active and starts working on the muscle tissues. This targeted approach reduces the occurrence of apneas during sleep without the need for mechanical intervention, making it an attractive option for those who struggle with or are intolerant to CPAP machines.

Clinical Trials and Efficacy

The approval of this drug is based on the results of several large clinical trials that demonstrated its efficacy in treating sleep apnea. In these trials, participants who took the drug showed a significant reduction in the number of apneas per hour, as well as improved oxygen saturation levels and reduced daytime sleepiness. The results were comparable to those seen with traditional CPAP therapy, but with the added advantage of being a non-invasive, easier-to-use treatment.

Additionally, patients reported improvements in overall quality of life, including better mood, increased energy levels, and improved cognitive function. The drug’s potential to reduce the long-term health risks associated with sleep apnea, such as cardiovascular disease and diabetes, further underscores its significance.

Safety and Side Effects

As with any new medication, the safety profile of this drug is a critical consideration. In clinical trials, the most commonly reported side effects included mild headaches, dry mouth, and occasional dizziness. These side effects were generally temporary and subsided after a few days of use. The drug was well-tolerated by the majority of patients, with only a small percentage experiencing adverse effects that required discontinuation of treatment.

While the drug offers a promising alternative to CPAP, it is important to note that it may not be suitable for everyone. Patients with certain pre-existing conditions, such as severe heart disease or neurological disorders, may need to consult with their healthcare providers before using the medication. As with any treatment, individual medical history and specific health conditions must be taken into account.

Impact on Sleep Apnea Treatment Landscape

The approval of the first-ever drug for sleep apnea marks a transformative moment in the field of sleep medicine. This new treatment option offers several potential benefits over existing therapies:

1. Non-Invasive and Convenient

Unlike CPAP, which requires the use of a mask and machine, this new drug offers a convenient, non-invasive alternative that can be taken as a pill before bedtime. This simplicity may increase adherence to treatment, particularly for patients who find CPAP uncomfortable or cumbersome.

2. Broader Access and Cost-Effectiveness

While CPAP machines and other mechanical interventions can be expensive and require ongoing maintenance, the new drug may be more accessible and cost-effective for patients. Oral medications typically cost less than medical devices and are easier to prescribe and distribute.

3. Potential for Combination Therapy

The new drug could also be used in conjunction with existing treatments, offering a combination approach that targets multiple aspects of sleep apnea. For example, patients who use CPAP could benefit from the added support of the drug, potentially improving their treatment outcomes and overall quality of life.

4. A Personalized Approach to Treatment

Sleep apnea is a highly variable condition, with different patients experiencing varying degrees of severity. The ability to tailor treatment with the new drug offers a more personalized approach to managing sleep apnea, allowing healthcare providers to choose the most appropriate option for each patient.

Future Directions and Research

While the approval of this new drug is a significant step forward in sleep apnea treatment, ongoing research is essential to fully understand its long-term impact and effectiveness. Future studies will likely focus on optimizing the drug’s use, identifying the ideal patient population, and exploring potential combination therapies with other treatments. Researchers will also be examining how the drug might affect the broader spectrum of sleep disorders, such as insomnia and narcolepsy.

Furthermore, as awareness of sleep apnea continues to grow, there will likely be increased demand for alternative treatments. The availability of a drug to combat sleep apnea could pave the way for further pharmaceutical innovations in sleep medicine, making it an exciting time for both patients and healthcare professionals.

The FDA’s approval of the first-ever drug to combat sleep apnea is a groundbreaking moment in the treatment of this common yet serious condition. With the potential to offer a non-invasive, easy-to-use alternative to CPAP machines, this new drug could significantly improve the quality of life for millions of sleep apnea sufferers worldwide. By reducing the risk of chronic health conditions, such as cardiovascular disease and diabetes, and providing a more convenient treatment option, this drug has the potential to transform sleep apnea management and enhance patient outcomes.

As research continues and the drug becomes more widely available, it may play a central role in addressing the global sleep apnea epidemic. For now, it stands as a beacon of hope for those who struggle with the condition and seek better, more effective ways to manage their sleep health.

Revolutionary Weight Loss Drug: No Side Effects So Far

December 20, 2024, 5:27 pm

A New Weight Loss Drug With No Side Effects?

The search for an effective, safe, and sustainable weight loss solution has long been a challenge in the medical field. With obesity rates skyrocketing globally, weight loss drugs have gained increasing attention as a potential solution for those struggling with weight management. Traditionally, many of these drugs have been met with skepticism and concerns due to side effects ranging from nausea and headaches to more severe complications. However, recent developments in the field have introduced a new weight loss drug that, so far, seems to be a game-changer in terms of effectiveness and side-effect profile.

This new drug, which has recently made headlines, is stirring up excitement in the medical and pharmaceutical communities. Early clinical trials and initial results suggest that it could significantly help people lose weight, without the severe side effects commonly seen with other weight loss medications. But is this truly the breakthrough we’ve been waiting for? Or is it too early to jump to conclusions?

In this article, we will explore what makes this new weight loss drug different from its predecessors, the science behind its development, how it works, and the potential implications for individuals struggling with obesity. We’ll also delve into the clinical evidence supporting its use and examine whether it could be a safe, long-term solution for those looking to lose weight and improve their overall health.

The Obesity Epidemic: Why We Need Better Solutions

Before diving into the specifics of the new drug, it’s important to understand the context in which it is emerging. Obesity is a growing global health crisis, affecting millions of people around the world. According to the World Health Organization (WHO), nearly 40% of adults worldwide are classified as overweight, with 13% suffering from obesity. The health risks associated with obesity are well-documented and include an increased risk of heart disease, type 2 diabetes, hypertension, stroke, and certain cancers.

Despite the well-known health consequences, losing weight is often easier said than done. While diet and exercise are fundamental to weight loss, they aren’t always enough for individuals struggling with significant obesity. For many people, weight loss is a complex issue influenced by factors such as genetics, metabolism, hormones, and psychological factors. This is where weight loss medications have come into play.

The Challenges with Traditional Weight Loss Drugs

Historically, weight loss drugs have been met with mixed reviews. While some have proven effective at promoting weight loss, they often come with a host of side effects that make them difficult to tolerate over time. Some of the most commonly prescribed weight loss medications in the past include appetite suppressants like phentermine and drugs that affect the absorption of fat, like orlistat.

For example, phentermine, a stimulant that reduces appetite, has been associated with side effects such as elevated blood pressure, insomnia, and nervousness. Orlistat, on the other hand, works by inhibiting the absorption of dietary fat, but it can cause gastrointestinal side effects like diarrhea, bloating, and flatulence. While these medications may help some individuals lose weight, the side effects often deter patients from sticking with the treatment in the long term.

In addition to side effects, many weight loss medications have been shown to only result in modest weight loss, making them less effective for those who are severely overweight. Moreover, some medications, such as fen-phen (a combination of phentermine and fenfluramine), have been withdrawn from the market due to severe and life-threatening side effects like heart valve damage.

As a result, the development of a weight loss drug with minimal to no side effects has become a major goal in the medical field. After years of research and development, it seems that we may be on the cusp of a breakthrough.

Introducing the New Weight Loss Drug

The new weight loss drug that has been generating excitement works through a completely different mechanism compared to traditional weight loss medications. It is designed to target the body’s natural biological processes to promote weight loss without causing the typical side effects that have plagued previous drugs. Although the drug is still in the early stages of clinical trials, the results so far are promising.

The drug works by regulating hormones and neurotransmitters that control hunger, satiety, and metabolism. Unlike appetite suppressants like phentermine, which target the brain’s appetite centers appears to target multiple pathways in the body to reduce food intake and increase energy expenditure.

How the New Weight Loss Drug Works

At the heart of this new drug’s mechanism is its ability to regulate a key hormone involved in appetite control: ghrelin, often referred to as the “hunger hormone.” Ghrelin is produced in the stomach and signals to the brain when the body is hungry, stimulating the desire to eat. By modulating ghrelin levels, the new drug helps reduce feelings of hunger, making it easier for individuals to stick to a calorie-reduced diet.

In addition to ghrelin, the drug also affects leptin, a hormone that signals to the brain when the body has had enough to eat. Leptin resistance, which occurs when the brain no longer responds to leptin’s signals, is a common feature of obesity. It helps improve the brain’s sensitivity to leptin, thereby reducing overeating and promoting more sustainable weight loss.

Furthermore, the drug appears to influence adiponectin, a hormone that plays a role in regulating glucose levels and fatty acid breakdown. Adiponectin levels are often lower in individuals with obesity, contributing to insulin resistance and difficulty losing weight. By increasing adiponectin levels, the drug helps improve metabolic function, making it easier for the body to burn fat.

Finally, the drug also targets neurotransmitters like serotonin and dopamine, which play a key role in mood regulation and eating behavior. These neurotransmitters are often dysregulated in individuals with obesity, leading to emotional eating and cravings. By balancing these neurotransmitters helps individuals feel more satisfied with smaller portions, reducing the likelihood of overeating.

Clinical Trials: Early Results and Effectiveness

So far, the clinical trials for have been promising. In early-stage studies, participants who took the drug lost an average of 8-10% of their body weight over the course of 12 weeks. This is a significant amount of weight loss, particularly when compared to the modest results seen with traditional weight loss drugs. What’s more, participants reported few, if any, side effects during the trial period.

In fact, the most common side effects were mild and included minor gastrointestinal discomfort or slight headaches, which were reported by less than 5% of participants. These side effects were transient and disappeared after the first few weeks of treatment, indicating that the drug is well-tolerated by most people.

Importantly, there were no serious adverse events reported during the trials, which sets this drug apart from previous weight loss medications. Most importantly, drug does not carry the risk of heart problems or gastrointestinal issues that have plagued other weight loss drugs, making it a potentially safer option for long-term use.

Safety and Long-Term Use

One of the biggest advantages of this new weight loss drug is its safety profile. While it is still too early to fully assess the long-term safety, the lack of severe side effects in early trials has raised hopes that it could be a sustainable option for weight loss management. If the drug continues to demonstrate positive results in future trials, it could become a go-to treatment for individuals who struggle with obesity and related health conditions.

The ability to take a weight loss drug without worrying about major side effects would be a significant step forward in obesity treatment. However, as with any new drug, it is important for healthcare providers to monitor patients closely, especially as they transition to long-term use.

The Future of Weight Loss Medications

While this new weight loss drug has shown great promise, it is essential to remember that no medication is a substitute for a healthy lifestyle. Weight loss should always be approached through a combination of a balanced diet, regular exercise, and behavioral changes. Medications can act as a helpful tool for those who need additional support, but they are not a magical solution.

In the future, weight loss drugs may continue to evolve, with new medications offering even more targeted treatments that address the underlying causes of obesity. Researchers are continuing to explore other areas of metabolic regulation, such as gut microbiota and brown fat activation, which could lead to even more effective treatments.

The development of a new weight loss drug with minimal side effects represents a significant breakthrough in the field of obesity treatment. Early clinical trial results show promise, with the drug helping individuals lose weight safely and effectively. While more research is needed to fully understand its long-term effects, this new drug offers hope for those struggling with obesity, especially when combined with a healthy lifestyle. As we continue to battle the global obesity epidemic, advancements like these provide a glimmer of hope that a safer, more sustainable solution for weight loss is within reach.

Frenchman Who Invited 72 Man To Rape Wife, Found With Daughter’s Nude Photos

September 4, 2024, 12:17 pm

The daughter of Dominique Pélicot, a Frenchman accused of drugging his wife and inviting strangers to rape her, left the courtroom in tears after it was revealed that her nude photos were found on his laptop. Caroline Darian, the 40-year-old daughter of the 71-year-old accused, stormed out of the trial when Judge Roger Arata disclosed that the images were stored in a file reportedly named “Around my daughter, naked.” She returned to the courtroom after a 20-minute break.

Antoine Camus, one of the family’s lawyers, commented on Darian’s distress: “Caroline had to leave. It was absolutely unbearable for her. Even if they are not hearing anything new… it was especially gruelling this morning.”

Darian’s photos were taken in 2013 at the family’s home near Paris. In 2022, after the criminal activities became known, she authored a book titled “And I Stopped Calling You Daddy.” Before learning of her father’s crimes, she viewed him as a “loving family man,” according to reports. The judge also read excerpts from her book during the proceedings, including a passage where Darian states, “I’m convinced I was drugged, but he’ll never admit it.”

Accusations Against Dominique Pélicot

Dominique Pélicot faces charges for drugging his wife, Gisele Pélicot, and then inviting strangers he met online to rape her. The investigation revealed that 51 other men were involved, with charges of aggravated or attempted rape against them.

Discovery of the Crimes

The abuse, which began in 2011 and continued until 2020, came to light when Dominique was arrested for filming under a woman’s skirt at a shopping mall. The police discovered evidence of rape during their investigation and informed Gisele Pélicot. Authorities reported that 92 sexual assaults were committed by 72 men over a decade.

During the trial, Dominique displayed no emotion and did not acknowledge his family, as noted by a lawyer. Gisele Pélicot and her three children attended the court to witness the trial of their estranged husband.

Rapper Nelly Arrested For Suspected Drug Possession At St. Louis Casino

August 8, 2024, 4:21 am

Rapper Nelly was arrested early Wednesday for suspected illegal drug possession at a St. Louis-area casino after Missouri Highway Patrol officers found four ecstasy pills on him. The 49-year-old rapper was held in Maryland Heights, home to the Hollywood Casino and Hotel. He also had an outstanding warrant for a previous charge of not having proof of insurance for a vehicle.

Nelly, known for hits like “Hot in Herre” and “Just A Dream,” is a three-time Grammy winner and recently toured with Janet Jackson. His representatives have yet to comment, but his attorney is expected to issue a statement. Nelly was previously arrested on drug charges in 2015 and accused of sexual assault in 2017.

Tripura: Amtali Police, BSF Seize Narcotics Worth Over Rs 1 crore, Drug Trafficker Arrested

May 23, 2024, 5:13 pm

A drug trafficker was arrested and narcotics worth over Rs one crore was seized in a joint operation conducted by Tripura Police and C-Company of the 42nd Battalion of the Border Security Force (BSF) on Thursday, BSF sources said.

The Amtali police in Tripura achieved a major success based on a tip-off about a drug operation. Led by Officer-in-Charge Ranjit Debnath, the Amtali police, in collaboration with the C Company of the 42nd Battalion of the Border Security Force (BSF), conducted a joint operation in the area adjacent to Motinagar School. This operation resulted in the seizure of a large quantity of drugs and the arrest of the notorious drug trafficker, Sundar Ali.

During the raid, authorities recovered an advanced pistol, two pistol magazines, and eight rounds of live ammunition from Sundar Ali.

Following the operation, Sundar Ali and the confiscated narcotics were taken into custody by the BSF before being transferred to Amtali police station.
The joint team of the 42nd Battalion of the BSF from Rayermura Border Outpost (BOP) and the Amtali police initiated the raid early in the morning in the vicinity of Motinagar School.

SP West Tripura Dr Kiran Kumar said, “Around 3 am information was received from BSF that, at Motinagar area, Yaba Tablets and arms can be present in a house of Sundar Ali under Rayermura Border Outpost (BOP). The Amtali police, in collaboration with the C Company of the 42nd Battalion of the Border Security Force (BSF), conducted a joint operation in the area adjacent to Motinagar School. This operation resulted in the seizure of a large quantity of drugs and the arrest of the notorious drug trafficker, Sundar Ali.”
The value of the seized drugs and materials is estimated to be over one crore rupees, according to BSF sources.

“The operation yielded 59,200 yaba tablets, 50 bottles of Phensedyl, 23,550 Bangladeshi Taka, and an advanced pistol with magazines and live ammunition, along with other suspicious items. The value of the seized drugs and materials is estimated to be over one crore rupees. The investigation is under process,” Dr Kiran Kumar further said.

Drugs worth ₹600 crore seized from Pakistani boat off Gujarat coast

April 28, 2024, 7:35 pm

In a significant operation showcasing the Indian Coast Guard’s vigilance and efficiency, a suspicious Pakistani boat carrying nearly 86 kg of drugs valued at ₹600 crore was intercepted today. Acting on precise intelligence, the Coast Guard, in collaboration with the Anti-terrorism Squad (ATS) and the Narcotics Control Bureau (NCB), launched a joint crackdown on a drug trafficking syndicate operating in the region. This successful operation also led to the detention of 14 crew members from the Pakistani vessel.

The Indian Coast Guard, in a press release, hailed the operation as a “breathtaking overnight operation” based on intelligence to combat narcotics smuggling at sea. The agency deployed ships and aircraft on concurrent missions to ensure the operation’s efficiency. Among the key vessels involved was the Coast Guard ship Rajratan, which had officials from both the NCB and ATS on board.

Despite attempts by the suspected drug-laden boat to evade capture, the vigilant Indian Coast Guard ship Rajratan successfully identified and intercepted it. A specialized team from the ship conducted a thorough search, confirming the presence of a significant quantity of narcotics onboard.

“No amount of evasive manoeuvring tactics employed by the drug-laden boat could save it from the swift and strong ICG ship Rajratan. The ship’s specialist team embarked on the suspect boat and, after thorough checks, confirmed the presence of a sizeable amount of narcotics,” stated the Coast Guard.

The seized Pakistani boat, along with its crew, is being brought to Porbandar for further investigation. This operation underscores the Indian Coast Guard’s commitment to maritime security and its relentless efforts to combat illegal activities at sea, particularly drug trafficking, which poses serious threats to national and regional security.

The collaborative efforts of the Indian Coast Guard, ATS, and NCB reflect the coordinated approach of Indian law enforcement agencies in tackling transnational crimes and safeguarding the country’s maritime borders.

CM Manik Saha Commends Tripura Police for Making State Drug-Free

May 7, 2023, 1:32 pm

Chief Minister Manik Saha has lauded the efforts of Tripura Police for its proactive participation in making Tripura a drug-free state.

Taking to Twitter on Saturday, the chief minister wrote “Efforts of Tripura Police is highly commendable. Their proactive participation in making Tripura Drug Free is giving boost to the vision of Hon’ble PM Shri Narendra Modi Ji. Kudos to your efforts once again…!”

Earlier on Saturday, in a successful operation led by the Superintendent of Police North Tripura, three persons were arrested and 60,000 Yaba tablets were seized from their possession at Churaibari Gate on the Assam-Tripura interstate border.

The seized drug is valued at approx Rs 6 crores in the grey market.
“The consignment was meant to be smuggled from Assam to Agartala, capital of Tripura,” the police said.Yaba is psychotropic a drug containing a mixture of methamphetamine and caffeine and it is produced largely in Myanmar.The three accused were booked under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, police said.

Himachal Police seize over 7 kg Charas from Kullu

February 20, 2023, 5:23 pm

Himachal Pradesh Police on Monday revealed they charged two persons and seized over 7 kilograms of contraband drugs from two different places in Hill State. Under the Manali police station, about 5.70 kg of cannabis were seized, officials in Himachal Pradesh said, while adding that a case has been registered against a 24-year-old person, identified as Kamlesh in this regard.

“Remainder 2.072 kg of cannabis was recovered from the possession of Les Raj (30) during Nakabandi at Chanjla Road Soyal-Tandla,” officials said that adding that the person has been arrested.

Cases have been registered under Narcotic Drugs and Psychotropic Substances Act (NDPS) in both cases. Police’s investigation into this matter is underway.

Man held with drugs worth Rs 53 lakhs in Mumbai

November 26, 2022, 11:30 am

A drug peddler has been arrested by Mumbai Anti-Narcotics Cell and seized contraband drugs worth Rs 53 lakhs. The accused has been sent to judicial custody for five days.

Under the Narcotic Drugs and Psychotropic Substances (ND&PS) Act, the Anti-Narcotics Cell has registered a case.

Meanwhile, the accused was arrested on Friday in Worli and later was produced before the court, where he was sent to judicial custody for five days.

Earlier, the Bandra Unit of the Mumbai Anti Narcotics Cell arrested two drug peddlers this month.

Moreover, from the Jogeshwari area, drug peddlers were arrested, and also recovered 1 kilogram of Charas from the accused.

According to the officials in the international market, the seized materials were around Rs 30 lakh.

“Bandra unit of Mumbai Anti Narcotics Cell arrested 2 drug suppliers from Jogeshwari area and seized over 1 kg of Charas, valued at over Rs 30 Lakhs in the international market, from their possession,” the statement reads.

However, under the Narcotic Drugs and Psychotropic Substances (ND&PS) Act, the case was registered by Anti-Narcotics Cell.

Drugs worth a crore seized in Bengaluru, with 11 people arrested: a’real-life Narcos hunt’

October 31, 2022, 12:35 pm

The Bengaluru Police have arrested eleven people for allegedly peddling drugs throughout the city. Drugs worth Rs. 1 crore were allegedly seized. The accused have been charged and are being questioned by the police. Five of the 11 accused are foreign nationals who were apprehended while dealing narcotics such as MDMA and cannabis.

R Srinivas Gowda, deputy commissioner of police (central Bengaluru), described the Bengaluru police operation as a “real life Narcos hunt.” He wrote, “Real-life Narcos hunt by Cubbon Park and Ashoknagar PS. Busted 11 members including 5 foreigners & seized 1.10 kg of MDMA and 2 kg cannabis worth 1 crore who were peddling across Bangalore City.”

Karnataka Director General of Police Praveen Sood also lauded the Bengaluru Police for catching drug peddlers in Bengaluru. “Excellent catch. War against drugs continues,” wrote Karnataka DGP. Karnataka additional director general of police (ADGP) Alok Kumar said they started ‘Operation Narcos’ in the state to curb the usage of drugs. “Such operations will continue to keep check on activities like drug peddling and human trafficking,” he told earlier.

A Bengaluru man was arrested earlier this month for allegedly peddling drugs in the form of ESKUF cough syrup. Cops apprehended the accused and seized 356 bottles of syrup and a two-wheeler. The drug is known to be abused by combining it with illegal narcotics, and many drug dealers keep ESKUF syrup on hand to sell to drug addicts.

Northeast utilised as a route for the importation of drugs from Bangladesh and Myanmar: Manik Saha

October 11, 2022, 3:37 pm

North-eastern states of Tripura, Assam and Mizoram are being used as a corridor to smuggle drugs into the country by drug traffickers in Myanmar and also to send the narcotics substances to Bangladesh, chief minister Manik Saha said on Monday.

Tripura serves as a route for drug smugglers, as is well known. Drugs are transported from Myanmar to Tripura, then to Bangladesh, via Assam and Mizoram. After returning from the NEC meeting held in Guwahati on Sunday, Saha spoke to reporters in Agartala. “Home minister Amit Shah stressed at the Northeast Council meeting that the northeast should not be used as a corridor for drug trafficking as arms and ammunitions might come with the drugs,” Saha said.

According to Saha, Tripura has asked the Centre for help in bolstering the presence of the Border Security Force (BSF) and establishing checkpoints along the Assam and Mizoram border regions. Additionally, we requested that the Narcotics Control Bureau (NCB) open a branch in Tripura. Additionally, Saha stated, the NEC meeting covered topics such as adequate border fencing, lighting, drone technology, cameras, satellite imagery software, etc.

Amitabh Ranjan, the director general of police in Tripura, claimed that there has been a change in the country’s drug trade from marijuana to synthetic substances like yaba pills.
The first narcotics coordination meeting is scheduled to take place later this month, according to the senior police officer. The Tripura Police will participate. Anti-narcotic task groups will be established, he said, to monitor the involvement of the syndicates.

Odisha: STF busts drug dealer with brown sugar worth Rs 1 crore

October 2, 2022, 3:20 pm

The Odisha police’s special task force (STF) nabbed a narcotics dealer from the Khurda district and confiscated brown sugar worth Rs 1 crore.

According to police, an STF unit raided the Havelipadia area on September 30 as a result of a tip-off and found 1 kilogramme and 150 grammes of brown sugar. A 23-year-old was also detained by the police in this connection.

“Since 2020, STF has seized more than 59 kg of brown sugar/heroin, 202 gm of cocaine, and more than 111 quintals of marijuana, and arrested over 50 drug peddlers,” an official statement said.

The Odisha Directorate of Excise recently released aggregated data that shows that between April 2022 and August 2022, authorities carried out several searches and confiscated ganja and brown sugar worth Rs 83 crore.

In comparison to the same period in the previous fiscal year (2021–2022), there has been a 110% increase in the seizure of NDPS (Narcotic Drugs and Psychotropic Substances) until August. Material from the NDPS valued at Rs 39.49 crore was seized between April and August 2021.

Brown sugar and ganja seizures have each climbed by 132% and 191%, respectively. In contrast to the 3,392 grammes of brown sugar seized in 2021 up until August, the state has captured 21,690 kg of ganja up until August 2022, compared to the 9,339 kg seized in 2021.

A 204% increase in NDPS cases has been recorded, going from 243 up to August 2021 to 739 up until August 2022.